Cabozantinib in Advanced Adrenocortical Carcinoma

NCT03612232 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Adrenocortical Carcinoma

Interventions

DRUG: Cabozantinib-s-malate

Sponsor

Wuerzburg University Hospital